Evidence map›Paper›PMID 38275994›Full record

ArticlePharmaceuticals (Basel, Switzerland)2023

Identification of a New Integration Site and Study on Site-Specific Integration in CHO-K1 Cells.

Hong Liu, Wei Zhang, Liping Xie, Youjia Hu

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Hong LiuDepartment of Biology, China State Institute of Pharmaceutical Industry, Shanghai 201203, China.
Wei ZhangDepartment of Biology, China State Institute of Pharmaceutical Industry, Shanghai 201203, China.
Liping XieDepartment of Biology, China State Institute of Pharmaceutical Industry, Shanghai 201203, China.
Youjia HuDepartment of Biology, China State Institute of Pharmaceutical Industry, Shanghai 201203, China.
Shanghai Institute of Pharmaceutical Industry · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Site-specific integration is an important approach used to address the problem of unstable cell lines in industry. In this study, we observed a reduction in the gene copy number and antibody production in a CHOK1 cell line BA03 capable of high antibody expression. We identified a new integration site named locus 7 in the intron region of the

Indexed as

CHO-K1CRISPR/Cas9etanerceptgene copy numbersite-specific integration

Identifiers

PMID38275994
PMCPMC10819697
OpenAlexW4389992066

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.